Department of Research, Karkinos Foundation, Mumbai, Maharashtra, India; Division of Cancer Biology, Karkinos Healthcare Pvt Ltd, Navi Mumbai, Maharashtra, India.
Division of Cancer Biology, Karkinos Healthcare Pvt Ltd, Navi Mumbai, Maharashtra, India.
Clin Lung Cancer. 2024 Dec;25(8):e420-e430.e20. doi: 10.1016/j.cllc.2024.07.011. Epub 2024 Jul 22.
The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights for implementation of precision therapies.
We analyzed the genomic profiles of 325 lung adenocarcinoma and 81 lung squamous carcinoma samples from Indian patients using targeted sequencing of 50 cancer related genes. Correlations between genomic alterations and clinical characteristics were computed using statistical analyses. Additionally, we identified distinct features of Indian NSCLC genomes by comparison across different ethnicities.
Our genomic analysis revealed several noticeable features of Indian NSCLC patients. Alterations in EGFR (45.8%), TP53 (27.4%), ALK (11.4%) and KRAS (10.2%) were predominant in adenocarcinoma, with 68% eligible for targeted therapies. Squamous carcinoma exhibited prevalent alterations in TP53 (40.7%), PIK3CA (17.3%), and CDKN2A (8.6%). We observed higher frequency of EGFR alterations (18.5%) in lung squamous carcinoma patients, significantly distinct from other ethnicities reported till date. Beyond established correlations, we observed 60% of PD-L1 negative squamous patients harbored TP53 alterations, suggesting intriguing therapeutic implications.
Our data revealed unique genomic variations of adenocarcinoma and squamous carcinoma patients, with significant indications for precision medicine and clinical practice of lung cancers. The study emphasizes the importance of clinical utility of NGS for routine diagnostics.
印度非小细胞肺癌（NSCLC）患者的基因组图谱仍未得到充分探索。我们揭示了印度 NSCLC 患者独特的基因组改变，从而为实施精准治疗提供了重要的分子见解。
我们使用 50 个与癌症相关基因的靶向测序，分析了 325 例肺腺癌和 81 例肺鳞癌样本的基因组图谱。使用统计分析计算了基因组改变与临床特征之间的相关性。此外，我们通过与不同种族的比较，确定了印度 NSCLC 基因组的独特特征。
我们的基因组分析揭示了印度 NSCLC 患者的几个显著特征。腺癌中 EGFR（45.8%）、TP53（27.4%）、ALK（11.4%）和 KRAS（10.2%）的改变最为常见，其中 68%有资格接受靶向治疗。鳞癌中 TP53（40.7%）、PIK3CA（17.3%）和 CDKN2A（8.6%）的改变更为常见。我们观察到肺鳞癌患者中 EGFR 改变的频率更高（18.5%），与迄今为止报道的其他种族明显不同。除了已建立的相关性外，我们还观察到 60%的 PD-L1 阴性鳞癌患者存在 TP53 改变，这提示了有趣的治疗意义。
我们的数据揭示了腺癌和鳞癌患者独特的基因组变异，为精准医学和肺癌的临床实践提供了重要依据。该研究强调了 NGS 在常规诊断中的临床应用的重要性。
